Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer | Journal of Clinical Oncology
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data | Future Oncology
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study) | International Journal of Clinical Oncology
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
New Treatment Options for Colorectal Cancer
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study | Scientific Reports
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
World-first confirmation of standard treatment for RAS wild-type colorectal cancer －Paper published in JAMA－ | National Cancer Center Japan
New treatment option for refractory metastatic colorectal cancer - trifluridine/tipiracil plus bevacizumab
Adding panitumumab vs. bevacizumab to chemotherapy extends OS in colorectal cancer subset
When more is better: bevacizumab treatment for patients with ovarian cancer | Fred Hutchinson Cancer Center
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
Frontiers | FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
A) Progression-free survival (PFS) and (B) overall survival (OS) for... | Download Scientific Diagram
Kaplan-Meier curves comparing overall survival for combination... | Download Scientific Diagram
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) | BMC Cancer | Full Text
Avastin and Lonsurf for Advanced Colorectal Cancer - NCI
